Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company pioneering therapies targeting cellular metabolism for genetically defined diseases. Founded in 2008 by prominent cancer researchers, the company initially focused on oncology before strategically pivoting to rare genetic metabolic disorders. Headquartered in Cambridge, Massachusetts, its work leverages deep expertise in metabolomics to develop small-molecule treatments for conditions with significant unmet medical need.

History

The company was established in 2008 by renowned scientists Lewis C. Cantley, Tak W. Mak, and Craig B. Thompson, whose foundational research illuminated the role of altered metabolism in cancer. This scientific premise attracted early venture capital from firms like Third Rock Ventures and ARCH Venture Partners. Its initial public offering on the NASDAQ in 2013 provided substantial capital to advance its pipeline. A major strategic shift occurred in 2021 when it sold its oncology portfolio to Servier for over $2 billion, allowing a full focus on its genetically defined metabolic disease franchises. This transaction included the transfer of assets like ivosidenib, which received approval from the U.S. Food and Drug Administration for certain leukemia patients.

Research and development

The core R&D strategy is centered on targeting key enzymes within cellular metabolic pathways. Its scientists employ advanced techniques in genomics and biomarker discovery to identify patient populations most likely to respond to therapy. A primary area of investigation is the pyruvate kinase pathway, crucial for red blood cell health and energy metabolism. This work has led to clinical programs for conditions like pyruvate kinase deficiency and thalassemia. The company also maintains research into cerebral small molecule metabolism, exploring treatments for disorders like phenylketonuria through collaborations with institutions like the Broad Institute.

Products

The company's lead commercial product is **mitapivat**, an oral activator of pyruvate kinase. It is approved in the United States, European Union, and other regions for the treatment of pyruvate kinase deficiency in adults. Mitapivat is also under regulatory review for non-transfusion-dependent thalassemia following positive results from the ENERGIZE trial. Another significant product, **enasidenib**, an inhibitor of the IDH2 enzyme, was developed for relapsed or refractory acute myeloid leukemia with an IDH2 mutation; this asset was part of the portfolio transferred to Servier. The clinical pipeline further includes investigational therapies for sickle cell disease and alpha-thalassemia.

Collaborations and partnerships

Strategic alliances have been fundamental to expanding its capabilities and global reach. A landmark collaboration began in 2010 with Celgene, which was later acquired by Bristol Myers Squibb, focusing on cancer metabolism targets; this partnership yielded royalties and milestone payments. The company has a significant agreement with Pfizer for the development and commercialization of mitapivat in territories outside the United States. Research partnerships with academic powerhouses like St. Jude Children's Research Hospital support its pediatric development programs. It also engages with patient advocacy groups such as the PK Deficiency Foundation to inform clinical trial design.

Corporate affairs

The company is led by Chief Executive Officer Brian Goff and operates from its headquarters in the thriving Kendall Square biotech hub. Following the divestiture of its oncology business, it functions as a focused, commercial-stage company with a lean structure of approximately 450 employees. Its financial strategy is geared towards funding late-stage clinical trials for its metabolic disease portfolio and pursuing potential business development opportunities. The corporate mission emphasizes transforming the lives of patients living with rare metabolic diseases through precision medicine.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Pharmaceutical companies established in 2008